Immune responses to Mycoplasma bovis proteins formulated with different adjuvants.
Most vaccines for protection against Mycoplasma bovis disease are made of bacterins, and they offer varying degrees of protection. Our focus is on the development of a subunit-based protective vaccine, and to that end, we have identified 10 novel vaccine candidates. After formulation of these candidates with TriAdj, an experimental tri-component novel vaccine adjuvant developed at VIDO-InterVac, we measured humoral and cell-mediated immune responses in vaccinated animals. In addition, we compared the immune responses after formulation with TriAdj with the responses measured in animals vaccinated with a mix of a commercial adjuvant (Emulsigen™) and 2 of the components of the TriAdj, namely polyinosinic:polycytidylic acid (poly I:C) and the cationic innate defense regulator (IDR) peptide 1002 (VQRWLIVWRIRK). In this latter trial, we detected significant IgG1 humoral immune responses to 8 out of 10 M. bovis proteins, and IgG2 responses to 7 out of 10 proteins. Thus, we concluded that the commercial adjuvant formulated with poly I:C and the IDR peptide 1002 is the best formulation for the experimental vaccine.
Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.|Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.
Tracy
T
Prysliak
Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.|Vaccine and Infectious Disease Organization - International Vaccine Centre (VIDO-InterVac), 120 Veterinary Road, Saskatoon, SK S7N 5E3, Canada.
Jose
J
Perez-Casal
D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D023181:Antimicrobial Cationic Peptides / Q000276:immunology; D001168:Arthritis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D001426:Bacterial Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology* / Q000517:prevention & control; D002908:Chronic Disease; D005260:Female; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000096:biosynthesis; D008297:Male; D009175:Mycoplasma Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D045682:Mycoplasma bovis / Q000276:immunology*; D011014:Pneumonia / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary; D011070:Poly I-C / Q000276:immunology; D013577:Syndrome; D014614:Vaccines, Synthetic
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D023181:Antimicrobial Cationic Peptides; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; C549067:IDR 1002; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; D011070:Poly I-C
CPPS; Mycoplasma bovis; chronic pneumonia and polyarthritis syndrome; nouveaux adjuvants; novel adjuvants; recombinant vaccine; vaccin recombinant; « chronic pneumonia and polyarthritis syndrome »